Peptides
Wolverine blend: BPC-157 plus TB4, with very limited human evidence
What is it?
“Wolverine” is a marketing name for a BPC-157 plus TB500/TB4 research blend. The catalog lists 5 mg + 5 mg and 10 mg + 10 mg vials. Because TB-500 can refer to either full-length thymosin beta-4 or a short fragment, the precise identity of the second ingredient needs lot-level confirmation before any study can be matched to the product. [1,2]
What do studies show?
Animal work on individual peptides motivates healing claims, but does not establish the blend’s effects. A 2021 retrospective clinic report contacted 16 patients after knee injections; four had received separate BPC-157 and TB4 injections, three of whom reported improvement. There was no placebo group, no standardized function measure, and no evidence that the injected TB4 matches this premixed catalog vial. The report cannot demonstrate cartilage repair, faster return to sport, or a causal benefit. [1]
Safety
Neither the small chart review nor animal work can establish long-term safety or sterile formulation of a blended research vial. An injury needs a proper diagnosis; using an experimental product could delay effective rehabilitation or treatment. FDA has flagged limited human safety information for BPC-157 and TB-500 fragment preparations. [2]
DOSE STATUS
How much?
EVIDENCE CONTEXT
Why?
The cited evidence does not establish a dose for this use or product.
No safe/effective Wolverine-blend dose is established. The vial labels give total inventory of each ingredient, not a studied schedule. The four-patient chart subgroup used a different delivery method and did not test this exact pre-mixed product, so its dosing cannot be transferred. No well-attributed exact-blend anecdotal amount with verified TB identity was found. [1,2]